Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 22 March 2002:
Vol. 295. no. 5563, pp. 2198 - 2199
DOI: 10.1126/science.295.5563.2198
Prev | Table of Contents | Next

News Focus

CANCER THERAPY:
Setbacks for Endostatin

Eliot Marshall

Harvard University's Judah Folkman electrified cancer researchers 5 years ago when he and his colleagues reported on a new compound that could shrink tumors in mice virtually to nothing by cutting off the blood supply to tumors, rather than by poisoning patients with toxic drugs. Now, as clinical trials of the widely heralded cancer treatment endostatin are about to be expanded, two groups report that they couldn't get it to work. Although these papers are not the first to raise questions about endostatin, they are among the most pointed.

Read the Full Text


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Angiogenesis-independent tumor growth mediated by stem-like cancer cells.
P. O. Sakariassen, L. Prestegarden, J. Wang, K.-O. Skaftnesmo, R. Mahesparan, C. Molthoff, P. Sminia, E. Sundlisaeter, A. Misra, B. B. Tysnes, et al. (2006)
PNAS 103, 16466-16471
   Abstract »    Full Text »    PDF »
Therapeutic Efficacy of Endostatin Exhibits a Biphasic Dose-Response Curve.
I. Celik, O. Surucu, C. Dietz, J. V. Heymach, J. Force, I. Hoschele, C. M. Becker, J. Folkman, and O. Kisker (2005)
Cancer Res. 65, 11044-11050
   Abstract »    Full Text »    PDF »
Recombinant human endostatin administered as a 28-day continuous intravenous infusion, followed by daily subcutaneous injections: a phase I and pharmacokinetic study in patients with advanced cancer.
A. H. G. Hansma, H. J. Broxterman, I. van der Horst, Y. Yuana, E. Boven, G. Giaccone, H. M. Pinedo, and K. Hoekman (2005)
Ann. Onc. 16, 1695-1701
   Abstract »    Full Text »    PDF »
A 27-Amino-Acid Synthetic Peptide Corresponding to the NH2-Terminal Zinc-Binding Domain of Endostatin Is Responsible for Its Antitumor Activity.
R. M. Tjin Tham Sjin, R. Satchi-Fainaro, A. E. Birsner, V.M. S. Ramanujam, J. Folkman, and K. Javaherian (2005)
Cancer Res. 65, 3656-3663
   Abstract »    Full Text »    PDF »
Endostatin dramatically inhibits endothelial cell migration, vascular morphogenesis, and perivascular cell recruitment in vivo.
D. K. Skovseth, M. J. T. Veuger, D. R. Sorensen, P. M. De Angelis, and G. Haraldsen (2005)
Blood 105, 1044-1051
   Abstract »    Full Text »    PDF »
Do antiangiogenic protein fragments have amyloid properties?.
M. F. B. G. Gebbink, E. E. Voest, and A. Reijerkerk (2004)
Blood 104, 1601-1605
   Abstract »    Full Text »    PDF »
Adeno-Associated Virus 2-Mediated Antiangiogenic Cancer Gene Therapy: Long-Term Efficacy of a Vector Encoding Angiostatin and Endostatin over Vectors Encoding a Single Factor.
S. Ponnazhagan, G. Mahendra, S. Kumar, D. R. Shaw, C. R. Stockard, W. E. Grizzle, and S. Meleth (2004)
Cancer Res. 64, 1781-1787
   Abstract »    Full Text »    PDF »
Amyloid Endostatin Induces Endothelial Cell Detachment by Stimulation of the Plasminogen Activation System.
A. Reijerkerk, L. O. Mosnier, O. Kranenburg, B. N. Bouma, P. Carmeliet, T. Drixler, J. C.M. Meijers, E. E. Voest, and M. F.B.G. Gebbink (2003)
Mol. Cancer Res. 1, 561-568
   Abstract »    Full Text »    PDF »
Induced Repatterning of Type XVIII Collagen Associates with Ectopic Sonic Hedgehog and Lung Surfactant C Gene Expression and Changes in Epithelial Epigenesis in the Ureteric Bud.
S. Vainio, Y. Lin, and T. Pihlajaniemi (2003)
J. Am. Soc. Nephrol. 14, S3-8
   Abstract »    Full Text »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)